SPG20 Antikörper (AA 500-550)
-
- Target Alle SPG20 Antikörper anzeigen
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
-
Bindungsspezifität
- AA 500-550
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser SPG20 Antikörper ist unkonjugiert
-
Applikation
- Immunoprecipitation (IP)
- Verwendungszweck
- Rabbit anti-SPG20 Antibody, Affinity Purified
- Homologie
- Mouse,Bovine
- Aufreinigung
- Affinity Purified
- Immunogen
- Between AA 500 and 550
- Isotyp
- IgG
- Top Product
- Discover our top product SPG20 Primärantikörper
-
anti-Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (AA 18-45), (N-Term) antibody
SPG20 Reaktivität: Human WB, FACS, IHC (p) Wirt: Kaninchen Polyclonal RB22531 unconjugated
anti-Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (AA 24-54), (N-Term) antibodySPG20 Reaktivität: Human WB, FACS, IHC (p), EIA Wirt: Kaninchen Polyclonal unconjugated
anti-Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (AA 1-350) antibodySPG20 Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
anti-Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (AA 431-480) antibodySPG20 Reaktivität: Human, Maus, Ratte, Rind (Kuh), Hund, Meerschweinchen, Pferd, Kaninchen, Fledermaus, Hamster, Affe, Schwein WB Wirt: Kaninchen Polyclonal unconjugated
anti-Spastic Paraplegia 20 (Troyer Syndrome) (SPG20) (Middle Region) antibodySPG20 Reaktivität: Human, Maus, Ratte, Rind (Kuh), Hund, Meerschweinchen, Pferd, Kaninchen, Zebrafisch (Danio rerio) WB Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
-
IP: 2 - 10 μg/mg lysate
WB: Not recommended. Use rabbit anti-SPG20 antibody ABIN7450761.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Konzentration
- 1000 μg/mL
- Buffer
- Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09 % Sodium Azide
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
- Haltbarkeit
- 12 months
-
- Target
- SPG20 (Spastic Paraplegia 20 (Troyer Syndrome) (SPG20))
- Andere Bezeichnung
- SPG20 (SPG20 Produkte)
- Synonyme
- SPARTIN antikoerper, TAHCCP1 antikoerper, AI840044 antikoerper, C79168 antikoerper, mKIAA0610 antikoerper, spartin antikoerper, Spg20 antikoerper, spg20a antikoerper, zgc:172059 antikoerper, spg20b antikoerper, zgc:153766 antikoerper, spartin antikoerper, spastic paraplegia 20, spartin (Troyer syndrome) homolog (human) antikoerper, spartin a antikoerper, spartin b antikoerper, SPART antikoerper, Spg20 antikoerper, Spart antikoerper, sparta antikoerper, spartb antikoerper
- Hintergrund
- Background: Spastic paraplegia 20 protein (SPG20) is a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Mutations associated with the SPG20 gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome) [taken from NCBI Entrez Gene (Gene ID: 23111)].
- Gen-ID
- 23111
- UniProt
- Q8N0X7
- Pathways
- Regulation of Cell Size, SARS-CoV-2 Protein Interaktom
-
